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pathologic involvement in IgA nephropathy with
normotension, normal renal function and mild
proteinuria
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Background: IgA nephropathy (IgAN) may progress to renal failure for some patients without any clinical risk
factors and it is not unusual to find severe pathologic damage in clinically mild IgAN. We therefore investigated
whether urinary kidney injury molecule-1 (KIM-1) was related to pathologic involvement in clinically mild IgAN.
Methods: Urinary KIM-1/creatinine of 51 IgAN patients with normotension, normal renal function and
proteinuria < 1.0 g/24 h were tested. Relationships between urinary KIM-1 and pathologic features were analyzed.
Results: Eighteen of the 51 patients had elevated urinary KIM-1. The tubular atrophy/interstitial fibrosis was more
severe in patients with elevated urinary KIM-1 than that in patients with normal urinary KIM-1 (T0/T1/T2, 13/5/0 vs.
33/0/0, P = 0.004). Proportion of glomeruli containing cresecents was higher in patients with elevated urinary KIM-1
than that in patients with normal urinary KIM-1 (50% vs. 18%, P = 0.026). Urinary KIM-1 correlated with the proportion
of total crescents (R = 0.303, p = 0.031) and fibrous crescents (R = 0.456, p = 0.001), but did not correlate with the
proportion of cellular crescents or fibrocellular crescents. Although the proportion of vascular lesions was higher
in patients with elevated urinary KIM-1 (44.4%) than that in patients with normal urinary KIM-1 (18.1%), the difference
was not significant (p = 0.057). There was no difference of the response to treatment between patients with and
without elevated urinary KIM-1 during a short-term follow-up.
Conclusions: Urinary KIM-1 is a reflection of tubularinstitial injury. For patients with clinically mild IgAN, high urinary
KIM-1 is related to relatively severe pathologic involvement on renal biopsy.
Keywords: KIM-1, IgA nephropathy, Oxford classificationBackground
Immunoglobulin A nephropathy (IgAN) which is the most
common form of primary glomerulonephritis, is clinically
heterogeneous and 20–40% of patients will progress to
end-stage renal disease (ESRD) eventually after diagnosis
[1,2]. Some clinical risk factors have been reported to
link with progressive IgAN including hypertension, pro-
teinuria >1.0 g/day, and reduced glomerular filtration
rate (GFR), but it is not unusual to find patients with* Correspondence: shanlin_55@163.com
†Equal contributors
1Department of Nephrology, General Hospital of Tianjin Medical University,
Tianjin 300052, China
Full list of author information is available at the end of the article
© 2014 Xu et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.significant histological damage despite the absence of
clinical risk factors [3-7]. Since IgAN may be progressive
for some patients without clinical risk factors [8], renal
biopsy seems to be needed for all patients with suspected
IgAN [9]. However, renal biopsy is an invasive examin-
ation and not all the patients with clinically trivial disease
can be persuaded to accept renal biopsy, so a noninvasive
biomarker for assessment of the severity of pathologic
involvement is needed.
Tubular/interstitial injury has been indicated to have
predictive value of the prognosis of IgAN [10-13]. Kidney
injury molecule-1 (KIM-1) is a protein expressed on renal
proximal tubule epithelial cells and is a sensitive biomarker
for proximal tubule injury [14,15]. Urinary KIM-1 has beenThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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treatment response in IgAN [16-19]. However, previous
studies mainly focused on the value of the urinary KIM-1
in the prediction of renal survival and all these studies
involved patients with IgAN from clinically trivial to very
severe. Thus, the value of urinary KIM-1 in IgAN with-
out clinical risk factors is unclear. We hypothesize that
urinary KIM-1 might be a valuable biomarker indicating
significant histological damage in clinically trivial patients.
In the current study, we detected the levels of urinary
KIM-1 in 51 IgAN patients with normotension, normal
renal function and mild proteinuria, and analyzed the
relationships between urinary KIM-1 and pathologic
variables identified by the recently published Oxford
classification of IgAN.Methods
Selection of patients
Fifty-one patients, aged >14 years, with renal-biopsy-
proven IgAN, from Tianjin Medical University General
Hospital between October 2011 and November 2013 were
enrolled. Normotension was defined as systolic blood pres-
sure <140 mmHg and diastolic blood pressure <90 mmHg;
Normal renal function was defined as serum creatin-
ine < upper limit of test (100 μmol/L); Mild proteinuria
was defined as proteinuria <1 g/24 h. Clinical and labora-
tory data were collected at the time of renal biopsy.
Patients with secondary causes of mesangial IgA deposits,
such as Henoch–Schonlein purpura or with comorbid
conditions such as diabetes mellitus, liver disease or
systemic lupus erythematosis, were excluded from this
study. Twenty healthy volunteers were used as normal
control. To analyze the relationship between urinary
KIM-1 and cresecents, eighteen patients who were
diagnosed as crescentic IgAN (defined as crescents in
more than 50% of glomeruli on biopsy specimens) were
also enrolled. The research was in compliance of the
declaration of Helsinki and approved by the ethic com-
mittee of Tianjin Medical University General Hospital.
Informed consent was obtained from each participant.
For participants under the age of 18, written informed
consents were obtained from the parents.Clinical and laboratory information
Clinical and laboratory data collected included the
following: gender, age (years), time from onset (months),
with/without prior infection, with/without gross hema-
turia, systolic and diastolic arterial pressure (mmHg),
proteinuria (g/24 h), serum creatinine (μmol/L), estimated
glomerular filtration rate (eGFR, ml/min/1.73 m2), serum
IgA level (mg/dL) and serum Complement 3 level (mg/dL).
eGFR was calculated with an equation developed by
adaptation of the Modification of Diet in Renal Disease(MDRD) equation on the basis of data from Chinese
chronic kidney disease patients [20].
Evaluation of pathologic involvement
The minimum number of glomeruli in renal biopsy to
allow the inclusion in the study was ten. The four patho-
logic variables of the Oxford classification were scored
as follows [21,22]: Mesangial score: ≦0.5 (M0) or > 0.5
(M1); Segmental glomerulosclerosis: absent (S0) or present
(S1); Endocapillary hypercellularity: absent (E0) or present
(E1); Tubular atrophy atrophy/interstitial fibrosis: ≦25%
(T0), 26–50% (T1) or >50% (T2). In addition, according to
the recommendation of Oxford classification, there was a
summary of the total number of glomeruli and the number
with crescents and global glomerulosclerosis. Vascular
lesions included hyaline change and wall thickening. Wall
thickening was evaluated as the ratio of luminal diameter
to outer diameter, and was considered to be present when
the ratio was less than 0.5. Two pathologists who were
blinded to patients’ data examined the slides separately.
Differences in scoring were resolved by re-reviewing the
biopsies and coming to consensus.
Detection of urinary KIM-1
Urine samples were collected and centrifuged at 1500 g
for 10 min to remove cellular components, and the super-
natant was frozen at −80°C until use. Urine samples from
20 normal individuals were collected as controls. Urinary
KIM-1 was measured by ELISA using a commercial kit
(R&D Systems, DKM100) in accordance with the man-
ufacturer’s guidelines. The lowest limit of detection for
this assay was 0.046 ng/mL. The inter-assay coefficient
of variation (CV) was 6.7%, and the intra-assay CV was
4.2%. The urinary KIM-1 level was standardized with
urine creatinine (ng/mg). Adjusted urinary KIM-1 was
expressed as urinary KIM-1 concentration/creatinine con-
centration (ng/mg).
Statistical analysis
The quantitative data were expressed as mean ± standard
deviation or median with interquartile range as appropri-
ate. Differences of quantitative parameters with normal
distribution between groups were assessed using the inde-
pendent t-test. Differences of quantitative parameters with
abnormal distribution between groups were assessed
using the non-parametric test. Paired samples were
assessed using the paired t-test. Differences of qualitative
data were compared using chi-square test. The Spearman
coefficient correlation was used to analyze correlation
among various parameters. A P-value of less than 0.05
was considered to be statistically significant. Analysis was
performed with SPSS statistical software package (version
17.0, Chicago, Ill, USA).
Figure 1 Urinary KIM-1 in patients with mild IgAN and controls.
The dotted line represented the value of 95 percentile of the urinary
KIM-1 of normal controls.
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Clinical and pathological characteristics of patients with
mild IgAN
The clinical parameters of patients with mild IgAN were
shown in Table 1.
The distribution of pathologic variables defined by the
Oxford classification was as follows: M0/M1: 42/9 (82.4/
17.6%); S0/S1: 45/6 (88.2/11.8%); E1/E2: 44/7 (86.3/13.7%)
and T0/T1/T2: 46/5/0 (90.2/9.8/0.0%). The median per-
centage of glomeruli with crescents was 0.0% with an
interquartile range between 0.0% and 35.0%. The median
percentage of glomeruli with global glomerulosclerosis
was 0.0% with an interquartile range between 0.0% and
40.0%. Among all 51 patients, 14 were with vascular
lesions (hyaline change and/or wall thickening).
Urinary KIM-1 in patients and normal controls
The urinary KIM-1 was significantly higher in patients with
mild IgAN than that in normal controls [0.42 (0.18-1.64)
vs. 0.27 (0.16-0.89) ng/mg, P = 0.046] (Figure 1). Since the
level of urinary KIM-1 in normal controls was not normally
distributed, the value of 95 percentile (0.52 ng/mg) was
considered as a cut-off point. Patients were therefore
divided into two groups according to the level of urinary
KIM-1 [i.e. patients with elevated urinary KIM-1 (>0.52 ng/
mg, n = 18) and patients without elevated urinary KIM-1
(≤0.52 ng/mg, n = 33)].
Comparison of EMST scores between patients with and
without elevated urinary KIM-1
As shown in Table 2, there was no significant difference
of all clinical parameters between patients with and
without elevated urinary KIM-1. As for comparison of
EMST scores, there was no significant difference of the
distributions of the scores of mesangial hypercellularity
(M), segmental glomerulosclerosis (S), and endocapillaryTable 1 Clinical parameters of 51 patients with mild IgAN
Characteristic
Male/female (n) 19/32
Age (years) 29.08 ± 7.96
Time from onset (months) 4(0.33, 84)
With/without prior infection 23/28
With/without gross hematuria 25/26
Systolic blood pressure (mmHg) 117.15 ± 12.05
Diastolic blood pressure (mmHg) 73.11 ± 9.05
Proteinuria (g/24 h) 0.56 ± 0.22
Serum creatinine (μmol/L) 74.75 ± 12.98
eGFR(ml/min/1.73 m2) 101.21 ± 24.50
Serum IgA (mg/dL) 335.47 ± 118.43
Serum Complement 3 (mg/dL) 94.42 ± 21.18
Data are expressed as mean ± SD or median with interquartile range.hypercellularity (E) between two groups, while proportion
of patients with T1 score of tubular atrophy/interstitial
fibrosis (T) was significantly higher in patients with ele-
vated urinary KIM-1 than that in patients without elevated
urinary KIM-1.
Since EMST scores were designed based on IgAN
patients with proteinuria >0.5 g/24 h, 31 patients with
proteinuria 0.5 ~ 1.0 g/24 h were then analyzed. For
these patients, similar results were found. Proportion of
T1 score was significantly higher in patients with elevated
urinary KIM-1 than that in patients without elevated
urinary KIM-1, and no difference of the scores of E, M
and S was found between patients with and without
elevated urinary KIM-1 (Table 3).
Comparison of glomeruli with cresecents and global
glomerulosclerosis between patients with and without
elevated urinary KIM-1
Besides EMST scores, proportions of glomeruli with
extracapillary proliferation (cresecents) and global glomer-
ulosclerosis between two groups were also compared.
Proportion of glomeruli with cresecents was significantly
higher in patients with elevated urinary KIM-1 than that
in patients without elevated urinary KIM-1. There was no
significant difference of the proportion of glomeruli with
global glomerulosclerosis between two groups (Table 2).
Comparison of vascular lesions between patients with
and without elevated urinary KIM-1
Among 14 patients with vascular lesions, 8 patients were
with elevated urinary KIM-1 and 6 patients were without
elevated urinary KIM-1. Although the proportion of
patients with vascular lesions was higher in patients
Table 2 Comparison of the clinical and pathologic parameters between patients with and without elevated urinary
KIM-1/Cr
Variable Without elevated urinary
KIM-1/Cr (n = 33)
With elevated urinary
KIM-1/Cr (n = 18)
P value
Male/female (n) 11/22 8/10 0.547
Age (years) 30.03 ± 7.96 27.33 ± 7.89 0.252
Time from onset (months) 5(0.5, 60) 3(0.33, 84) 0.501
With/without prior infection 13/20 10/8 0.378
With/without gross hematuria 16/17 9/9 1.000
Systolic blood pressure (mmHg) 118.18 ± 10.95 115.28 ± 13.98 0.416
Diastolic blood pressure (mmHg) 74.24 ± 8.11 71.11 ± 10.51 0.241
Proteinuria (g/24 h) 0.52 ± 0.20 0.62 ± 0.24 0.149
Serum creatinine (μmol/L) 74.24 ± 13.09 75.69 ± 13.10 0.707
eGFR(ml/min/1.73 m2) 105.24 ± 23.19 104.56 ± 16.27 0.912
Serum IgA (mg/dL) 318.05 ± 111.82 374.27 ± 127.36 0.180
Serum Complement 3 (mg/dL) 93.73 ± 23.15 96.38 ± 19.04 0.774
Mesangial hypercellularity (M0/M1) 29/4 13/5 0.249
Segmental glomerulosclerosis (S0/S1) 28/5 17/1 0.405
Endocapillary hypercellularity (E0/E1) 29/4 15/3 0.686
Tubular atrophy/interstitial fibrosis (T0/T1/T2) 33/0/0 13/5/0 0.004*
With/without extracapillary proliferation (cresecents) 6/27 9/9 0.026*
With/without global glomerulosclerosis 13/20 10/8 0.378
With/without vascular lesions 6/27 8/10 0.057
*Being statistically significant. Since there was no patient with T2 in two groups, distribution of the variable of tubular atrophy/interstitial fibrosis was compared
by chi-square test.
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without elevated urinary KIM-1 (18.1%), the difference
was not significant (p = 0.057) (Table 2).
Analysis of the relationship between urinary KIM-1 and
glomeruli with cresecents
Since there were more glomeruli with cresecents in
patients with elevated urinary KIM-1, relationship between
urinary KIM-1 and cresecents was further analyzed. The
urinary KIM-1 of patients with cresecents was higher than
that of patients without cresecents [0.68 (0.18-1.64) vs.
0.385 (0.18-1.28) ng/mg, P = 0.046]. The proportion of
patients with T1 score was significantly higher in
patients with cresecents (T0/T1/T2: 11/4/0) than that in
patients without cresecents (T0/T1/T2: 35/1/0) (p = 0.022).Table 3 Comparison of the EMST scores in patients with prot
Variable Without elevated urinary K
Mesangial hypercellularity (M0/M1) 17/2
Segmental glomerulosclerosis (S0/S1) 15/4
Endocapillary hypercellularity (E0/E1) 17/2
Tubular atrophy/interstitial fibrosis (T0/T1/T2) 19/0/0
*Being statistically significant. Since there was no patient with T2 in two groups, dis
by chi-square test.Correlation analysis showed that for all 51 patients with
proteinuria 0 ~ 1.0 g/24 h, urinary KIM-1 correlated with
the percentage of glomeruli containing total crescents
(Figure 2A). Further analysis indicated urinary KIM-1
correlated with the percentage of glomeruli containing
fibrous crescents (Figure 2B), but did not correlate with
the percentage of glomeruli containing cellular crescents or
cellular/fibrous crescents. Similar results were found in
patients with proteinuria 0.5 ~ 1.0 g/24 h (Figure 2C and D).
To further investigate whether the correlation found
in patients with mild IgAN was valid in various stage of
IgAN, correlation analysis was also made in 18 patients
diagnosed as crescentic IgAN. For these patients, the
percentage of glomeruli with crescents ranged from 50%
to 95%. Unlike patients with mild IgAN, 72% patientseinuria 0.5 ~ 1.0 g/24 h





tribution of the variable of tubular atrophy/interstitial fibrosis was compared
Figure 2 Association between urinary KIM-1 and glomeruli with cresecents for patients with mild IgAN. A: Association between urinary
KIM-1 and the proportion of total cresecents for all patients with mild IgAN. B: Association between urinary KIM-1 and the proportion of fibrous
cresecents for all patients with mild IgAN. C: Association between urinary KIM-1 and the proportion of total cresecents for the subgroup of patients
with proteinuria 0.5 ~ 1.0 g/24 h. D: Association between urinary KIM-1 and the proportion of fibrous cresecents for the subgroup of patients with
proteinuria 0.5 ~ 1.0 g/24 h.
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13). Correspondingly, the urinary KIM-1 of patients with
crescentic IgAN was significantly higher than that of pa-
tients with mild IgAN [1.34 (0.35-3.11) vs. 0.42 (0.68-1.64)
ng/mg, P < 0.001]. However, no correlation between the
percentage of glomeruli with crescents and urinary KIM-1
was found in patients with crescentic IgAN,
Comparison of the response to treatment between
patients with and without elevated urinary KIM-1
Twenty-two patients were followed up for 3 ~ 24 months.
During follow up, 16 patients were treated with ACEis
and/or ARBs and 7 patients were treated with immuno-
suppressive therapy (13.5%). The mean follow-up duration
was 11.41 ± 6.06 months. After treatment, the follow-up
proteinuria decreased significantly (0.53 ± 0.24 ng/mg)
compared with the baseline level (ng/mg, 0.53 ± 0.24 vs.
0.62 ± 0.23 P = 0.039). There was no significant difference
of the baseline proteinuria between patients with and
without elevated urinary KIM-1 (g/24 h, 0.57 ± 0.23 vs.
0.70 ± 0.22, P = 0.218). There was also no significant differ-
ence of the follow-up proteinuria between patients with
and without elevated urinary KIM-1 (g/24 h, 0.46 ± 0.19
vs. 0.64 ± 0.28, P = 0.09).Discussion
Urinary KIM-1 has been considered to be a biomarker for
tubulointerstitial damage and repair and is not detected
in severely damajged tubules [23]. Inconsistent results
about the relationships between urinary KIM-1 and clinical
parameters in IgAN have been derived by previous studies.
The earliest study on the correlation between urinary
KIM-1 and IgAN was made by Van Timmeren et al. [23].
The authors studied 102 patients with various kinds of
kidney diseases including IgAN and found that urinary
KIM-1 correlated negatively with renal function but not
with proteinuria. However, there were only 10 patients
with IgAN in that study. Subsequent studies focusing on
patients with various stages of IgAN got different results
[16,18]. In the current study, we found no correlation
between urinary KIM-1 and proteinuria, as well as between
urinary KIM-1 and renal function for IgAN patients with
normotension, normal renal function and mild proteinuria,
and the proportion of patients with elevated urinary KIM-1
was lower than previous studies [16,18]. We speculated that
the heterogeneity of the selected patients might contribute
to the differences of the results.
Oxford classification is the first specially-designed patho-
logical system for evaluating the prognosis of IgAN. Among
Xu et al. BMC Nephrology 2014, 15:107 Page 6 of 7
http://www.biomedcentral.com/1471-2369/15/107all 4 variables, tubular atrophy/interstitial fibrosis has been
indicated to have the most predictive value by different
validation studies [10-12]. In the current study, the patients
with elevated urinary KIM-1 had more severe tubulointer-
stitial injury (5/18 patients with elevated urinary KIM-1 had
T1 score, while no patient with normal urinary KIM-1 had
T1 score). Although no difference of the response to treat-
ment between patients with and without elevated urinary
KIM-1 was observed during a short-term follow-up, it
seems that the long-term prognosis of the patients with
elevated urinary KIM-1 should be paid more attention.
Although KIM-1 is a sensitive and specific biomarker
for the tubulointerstitial damage, elevated urinary KIM-1
can be observed not only in the kidney diseases charac-
terized mainly by tubulointerstitial damage, but also in
that characterized exclusively by globular damage (such
as minimal change disease) [23]. In these diseases, tubu-
lointerstitial damage should be due to reabsorption of
protein. So urinary KIM-1 is a marker of the disease
activity, however when tubules and interstitium are
extremely damaged, KIM-1 will disappear. In the current
study, significant correlation between urinary KIM-1 and
crescent formation was found in patients with mild
IgAN. Previous studies indicated more than 20% of
IgAN patients could be found to have crescents on the
initial biopsy [24-26]. Poor prognosis of crescentic
IgAN has been generally recognized by clinicians [25].
Coexistence of the cellular, fibrocellular and fibrous
crescents reflects the process of slow progression of IgAN.
Although crescent formation was not demonstrated to
be an independent risk factor of ESRD in the Oxford
classification, the significance of crescent formation in
IgAN should not be neglected, because patients with
rapidly progressive kidney failure were excluded when
developing the Oxford classification.
IgAN is a kind of glomerulopathy and the tubular/
interstitial injury should emerge following the glomerular
injury. The chronic glomerular damage causes local
microcirculation barrier, and then causes kidney ischemia
and damages the tubules and interstitium. Although no
correlation between crescents and urinary KIM-1 was
found in 18 patients with crescentic IgAN, the urinary
KIM-1 level of these patients was higher than that of
patients with mild IgAN and the tubular/interstitial injury
was much more severe (72% patients with crescentic
IgAN were of T2 score). Thus, we speculated that cres-
cents formation might be able to cause tubular/interstitial
injury and then induce the expression of KIM-1 indirectly.
It was noteworthy that for patients with mild IgAN, it
was the fibrous crescent not the cellular crescent that
correlated with urinary KIM-1. Fibrillation of crescents
means the acute damage of glomeruli turn to be chronic
and irreversible, and the microcirculation of interstitium
will be injured inevitably. Thus, the correlation betweenfibrous crescents and urinary KIM-1 found in patients
with mild IgAN might be a reflection of the ischemic in-
jury of tubules and interstitium caused by the irreversible
glomerular damage.
Although the exact reason is still unclear, previous
studies indicated that vascular lesions in IgAN were very
common [27,28]. Since vascular lesions can influence the
blood supply to the glomeruli, tubules and interstitium
and cause more damage to the glomerular and tubuloin-
terstitial tissues, it might also influence the expression of
KIM-1. In the current study, no significant difference of
the incidence of vascular lesions between patients with
and without elevated urinary KIM-1 was found. However,
since the p-value of the comparison had reached 0.057,
we thought that the result might be reversed when the
number of patients could be enlarged enough.
Limitations
There are some limitations to the present study. First,
According to Oxford classification, the histologic lesions of
biopsy of patients with clinically mild IgAN were relatively
small. The proportion of patients with T1 was low and no
patient was found to be with T2. This might have an influ-
ence on the analysis of the relationship between urinary
KIM-1 and the tubulointerstitial injury. Second, urinary
KIM-1 was measured at a single time-point and it is
unclear whether the level of urinary KIM-1 fluctuates
on different occasions. Finally, since the time of follow-up
is short, we could not judge the long-term outcome of
these patients at present. A large-scale analysis with a long
time follow-up is warranted.
Conclusions
In conclusion, urinary KIM-1 is a reflection of tubuloin-
terstitial injury. For patients with IgAN without clinical
risk factors, high urinary KIM-1 level is related to relatively
severe pathologic involvement on renal biopsy. There was
no difference of the response to treatment during a short
time follow-up between patients with and without elevated
urinary KIM-1. However, since IgAN tends to progress
slowly, a long-term follow-up is still needed.
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